Melane Sampson, Author at BioTuesdays

Developments

BriaCell expands pipeline to ovarian cancer candidate

BriaCell Therapeutics (NASDAQ: BCTX, BCTXL; TSX: BCT) has announced progress in developing Bria-OVA+, its next generation, personalized, off-the-shelf, cell-based immunotherapy for ovarian cancer. According to the...

May 15, 2026

Executive Moves

ARS appoints Donn Casale as president

ARS Pharmaceuticals (NASDAQ: SPRY) has appointed Donn Casale as president, effective June 1, 2026, with Richard Lowenthal continuing to lead as CEO. Mr. Casale brings 25 years of biopharmaceutical commercial leadership...

May 13, 2026

Executive Moves

BetterLife appoints Doug Drysdale as executive chairman and director

BetterLife Pharma (CSE: BETR; OTCQB: BETRF; FSE: NPAU) has appointed its current corporate advisor, Doug Drysdale, as executive chairman and director. Mr. Drysdale was formerly CEO of Cybin (NYSE: CYBN) where he led the...

May 13, 2026

Executive Moves

Dr. Kyle Bauser joins Titan Partners as Director, Senior Research Analyst

Investment bank Titan Partners has announced that Kyle Bauser, Ph.D., has been appointed Director, Senior Research Analyst covering healthcare technologies. Dr. Bauser brings more than 12 years of experience in equity...

May 12, 2026

Developments

Rigel enters into licensing agreement with Arvinas and Pfizer

Rigel Pharmaceuticals (NASDAQ: RIGL) has announced that it has entered into an exclusive, global license agreement with Arvinas (NASDAQ: ARVN) and Pfizer (NYSE: PFE), subject to regulatory clearance, to develop...

May 12, 2026

Developments

MindMaze and Vibra ink partnership to scale neurotherapeutics across U.S.

MindMaze Therapeutics (SIX: MMTX) has announced the signing of a definitive channel partnership agreement with closely held Vibra Healthcare to introduce MindMaze’s FDA-cleared digital neurotherapeutics platform to U.S...

May 12, 2026

Developments

4basebio launches enzymatic ssDNA platform

4basebio (AIM: 4BB) has announced the commercial launch of its high-capacity single-stranded DNA (ssDNA) product line to accelerate the development of safer, more precise genetic therapies by enabling targeted gene...

May 11, 2026

Developments

Pentixapharm submits IND for hypertension diagnostic program

Pentixapharm Holding (Frankfurt Prime Standard: PTP) announced the submission of an Investigational New Drug (IND) application to the FDA for its lead CXCR4-targeted diagnostic program in treatment resistant...

May 11, 2026

Developments

JAMA Network Open publishes Red Light’s trial of psilocybin in cocaine use disorder

Red Light Holland (CSE: TRIP; FSE: 4YX; OTCQB: TRUFF) has highlighted the publication of a peer-reviewed randomized clinical trial in the Journal of American Medical Association (JAMA) Network Open evaluating a single...

May 8, 2026

Developments

Vistagen reports last patient visit in trial of fasedienol nasal spray in SAD

Vistagen (NASDAQ: VTGN) has announced that the last patient has completed the last visit in the randomized, double-blind, placebo-controlled portion of PALISADE-4, the Phase 3 clinical trial evaluating fasedienol nasal...

May 8, 2026

Author - Melane Sampson

BriaCell expands pipeline to ovarian cancer candidate

ARS appoints Donn Casale as president

BetterLife appoints Doug Drysdale as executive chairman and director

Dr. Kyle Bauser joins Titan Partners as Director, Senior Research Analyst

Rigel enters into licensing agreement with Arvinas and Pfizer

MindMaze and Vibra ink partnership to scale neurotherapeutics across U.S.

4basebio launches enzymatic ssDNA platform

Pentixapharm submits IND for hypertension diagnostic program

JAMA Network Open publishes Red Light’s trial of psilocybin in cocaine use disorder

Vistagen reports last patient visit in trial of fasedienol nasal spray in SAD

Subscribe